Evidence map›Paper›PMID 26314518›Full record

ArticleAmerican journal of obstetrics and gynecology2016

Injectable silk-based biomaterials for cervical tissue augmentation: an in vitro study.

Joseph E Brown, Benjamin P Partlow, Alison M Berman, Michael D House, David L Kaplan

Open access · greenAbstract read
In one paragraph

Article in American journal of obstetrics and gynecology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed, 1 pooled it
3.1field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 1 synthesis or guideline pooled it, 37 citations in OpenAlex.

  1. Pooled it
  2. Silk Fibroin Particle-Laden Sponges as a Multiphase Controlled Release Platform.Regenerative engineering and translational medicine · 2025
    Article
  3. Review
  4. Tissue Engineering for Cervical Function in Pregnancy.Current opinion in biomedical engineering · 2022
    Article
  5. Article
  6. Next generation strategies for preventing preterm birth.Advanced drug delivery reviews · 2021
    Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Ex vivo pregnant-like tissue model to assess injectable hydrogel for preterm birth prevention.Journal of biomedical materials research. Part B, Applied biomaterials · 2020
    Article
  12. Bioactive Silk Hydrogels with Tunable Mechanical Properties.Journal of materials chemistry. B · 2018
    Article
  13. Review
  14. Article
  15. Article
  16. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Joseph E BrownDepartment of Biomedical Engineering, Tufts University, Medford, MA.
Benjamin P PartlowDepartment of Biomedical Engineering, Tufts University, Medford, MA.
Alison M BermanDepartment of Biomedical Engineering, Tufts University, Medford, MA.
Michael D HouseDepartment of Obstetrics and Gynecology, Division of Maternal Fetal Medicine, Tufts Medical Center, Boston, MA.
David L KaplanDepartment of Biomedical Engineering, Tufts University, Medford, MA. Electronic address: david.kaplan@tufts.edu.
Tufts University · USTufts Medical Center · US

Funding

Translational Bioreactors - Engineering Complex TissuesP41EB002520 · NIBIB · TUFTS UNIVERSITY MEDFORD · PI KAPLAN, DAVID L. · 2004 to 2018
$16.7M
NIBIB NIH HHS P41 EB002520
6 · The paper itself

Abstract

backgroundCerclage therapy is an important treatment option for preterm birth prevention. Several patient populations benefit from cerclage therapy including patients with a classic history of cervical insufficiency; patients who present with advanced cervical dilation prior to viability; and patients with a history of preterm birth and cervical shortening. Although cerclage is an effective treatment option in some patients, it can be associated with limited efficacy and procedure complications. Development of an alternative to cerclage therapy would be an important clinical development. Here we report on an injectable, silk protein-based biomaterial for cervical tissue augmentation. The rationale for the development of an injectable biomaterial is to restore the native properties of cervical tissue. While cerclage provides support to the tissue, it does not address excessive tissue softening, which is a central feature of the pathogenesis of cervical insufficiency. Silk protein-based hydrogels, which are biocompatible and naturally degrade in vivo, are suggested as a platform for restoring the native properties of cervical tissue and improving cervical function.

objectiveWe sought to study the properties of an injectable, silk-based biomaterial for potential use as an alternative treatment for cervical insufficiency. These biomaterials were evaluated for mechanical tunability, biocompatibility, facile injection, and in vitro degradation. STUDY

designSilk protein solutions were cross-linked by an enzyme catalyzed reaction to form elastic biomaterials. Biomaterials were formulated to match the native physical properties of cervical tissue during pregnancy. The cell compatibility of the materials was assessed in vitro using cervical fibroblasts, and biodegradation was evaluated using concentrated protease solution. Tissue augmentation or bulking was demonstrated using human cervical tissue from nonpregnant hysterectomy specimens. Mechanical compression tests measured the tissue stiffness as a function of the volume of injected biomaterial.

resultsSilk protein concentration, molecular weight, and concentration of cross-linking agent were varied to generate biomaterials that functioned from hard gels to viscous fluids. Biomaterials that matched the mechanical features of cervical tissues were chosen for further study. Cervical fibroblasts cultured on these biomaterials were proliferative and metabolically active over 6 days. Biomaterials were degraded in protease solution, with rate of mass loss dependent on silk protein molecular weight. Injection of cervical tissue samples with 100 μL of the biomaterial resulted in a significant volume increase (22.6% ± 8.8%, P < .001) with no significant change in tissue stiffness.

conclusionCytocompatible, enzyme cross-linked silk protein biomaterials show promise as a tissue bulking agent. The biomaterials were formulated to match the native mechanical properties of human cervical tissue. These biomaterials should be explored further as a possible alternative to cerclage for providing support to the cervix during pregnancy.

Indexed as

Biocompatible MaterialsBiopolymersCell ProliferationCells, CulturedCell SurvivalCervix UteriElasticityFemaleFibroblastsFibroinsFibronectinsHumansHydrogelsInjectionsMaterials TestingMolecular WeightBiocompatible MaterialsBiopolymersFibroinsFibronectinsHydrogelsPronaseRecombinant Fusion Proteinssilk-like protein polymercervical shorteningcervical tissue bulkinghydrogelspreterm birthsilk protein

Identifiers

PMID26314518
PMCPMC4698015
OpenAlexW1123631797

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.